CTOs on the Move

Gyroscope Therapeutics

www.gyroscopetx.com

 
Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. The company was acquired by Novartis, a leading global medicines company, in February 2022.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.gyroscopetx.com
  • 2200 Renaissance Boulevard Suite 410
    King of Prussia, PA USA 19406
  • Phone: 267.523.2100

Executives

Name Title Contact Details

Similar Companies

89 North

89 North is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nacalai USA

Nacalai USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axion Pharmaceuticals

Axion Pharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RAPT Therapeutics

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.